Orchard Therapeutics plc
ORTXDelisted Jan 24, 2024- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001748907
Orchard Therapeutics plc was delisted on Jan 24, 2024; its insiders filed their last Form 4 on Jan 24, 2024; 47 institutions reported holding it in 13F filings for Q4 2023, worth $122.0M in total; no superinvestor held it.
Q3 2023 vs. Q2 2023
How the institutions holding Orchard Therapeutics plc changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 33 | 32 | −1 |
| Shares | 5.03M | 16.6M | +11.5M (+229.4%) |
| Value | $26.2M | $46.9M | +$20.7M (+79.1%) |
New holders (3)
Institutions that held Orchard Therapeutics plc at the end of Q3 2023 but not at the end of Q2 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Forefront Analytics, LLC | 14,183 | $109.6K | 0.06% |
| Susquehanna International Group, LLP | 13,445 | $104.3K | 0.00% |
| Qube Research & Technologies Ltd | 3 | $23 | 0.00% |
Sold out (4)
Institutions that held Orchard Therapeutics plc at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Temasek Holdings (Private) Ltd | 352,379 | $1.84M |
| Goldman Sachs Group Inc | 28,364 | $147.8K |
| Group One Trading, L.P. | 301 | $1.56K |
| Barclays PLC | 200 | $1.04K |